FOLH1 positive

P1, N=14, Completed, The Netherlands Cancer Institute | N=24 --> 14 | Recruiting --> Completed

Nevertheless, such systems can be essential for optimizing prostate cancer management and facilitating communication among imaging professionals, clinicians, and patients. This article outlines these systems and discusses potential strengths and weaknesses.

Early clinical experience with [¹⁷⁷Lu]Lu-PSMA radioligands and ongoing trials such as RENALUT and PRadR are exploring the feasibility of radioligand therapy targeting PSMA-positive ccRCC neovasculature. Although biological and kinetic barriers persist, PSMA-based imaging and therapy represent a feasible, rapidly translatable platform that bridges diagnosis and targeted treatment, marking a pivotal step towards personalised, imaging-guided management of advanced ccRCC.

P1/2, N=148, Active, not recruiting, OncoC4, Inc. | Recruiting --> Active, not recruiting

High tracer accumulation in 70% of the participants suggests a possible use for PSMA-directed radiopharmaceutical therapy in an end-stage setting. However, PSMA expression was not prognostic for outcome, possibly because of the small sample size.

P2, N=200, Active, not recruiting, Canadian Cancer Trials Group | Trial primary completion date: Jun 2026 --> Aug 2025

P3, N=450, Recruiting, Novartis Pharmaceuticals | Trial primary completion date: Dec 2027 --> Apr 2028

P1, N=0, Recruiting, The First Affiliated Hospital of Guangzhou Medical University; The First Affiliated Hospital of Guangzhou Medical University

P3, N=450, Recruiting, Novartis Pharmaceuticals | Trial primary completion date: Mar 2026 --> Dec 2027

This analysis identifies potential genomic predictors of response to 177Lu-PSMA-617, with NF1 and FOXA1 alterations associated with favorable outcomes and AR and TSG alterations with diminished response. These hypothesis-generating findings suggest genomic profiling may inform selection for PSMA-targeted therapy and warrant prospective validation in larger cohorts.

The biphenyl-based bispecific tracers developed in this study achieved high tumor affinity, prolonged retention, and notably reduced renal uptake in mouse models. [18F]AlF-NOTA-PSFA-1 emerged as the most promising candidate, demonstrating superior imaging performance over [68Ga]Ga-PSMA-11 in both preclinical and first-in-human evaluation.

Patients who have PSMA detected on a PET (positron emission tomography) scan will receive the treatment every 6 weeks for up to four cycles, with the possibility of two extra cycles if their cancer is stable or shrinking. The aim of the trial is to test a new treatment option for patients who have few remaining alternatives.